Global Restless Legs Syndrome Market 2015-2019

むずむず脚症候群(RLS)治療薬の世界市場2015-2019

◆タイトル:Global Restless Legs Syndrome Market 2015-2019
◆商品コード:IRTNTR6054
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年6月10日
◆ページ数:80
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、むずむず脚症候群(RLS)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、むずむず脚症候群(RLS)治療薬の世界市場規模及び予測、市場シェア、製品パイプライン分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・むずむず脚症候群(RLS)治療薬の世界市場:市場規模及び予測
・むずむず脚症候群(RLS)治療薬の世界市場:製品パイプライン分析
・むずむず脚症候群(RLS)治療薬の世界市場:地域別分析
・市場シェア
・購買基準
・市場成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About RLS
RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.
Technavio’s analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
Technavio’s report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Boehringer Ingelheim
• GlaxoSmithKline
• UCB
• XenoPort

[Other prominent vendors]
• Alexza Pharmaceuticals
• Astellas Pharma
• Axxonis Pharma
• Bayer Healthcare
• Impax Pharmaceuticals
• Luitpold Pharmaceuticals
• Merz Pharmaceuticals
• Mundipharma
• Newron Pharmaceuticals
• Serina Therapeutics
• Teva Neuroscience

[Market driver]
• High unmet medical needs
• For a full, detailed list, view our report

[Market challenge]
• Unknown disease etiology
• For a full, detailed list, view our report

[Market trend]
• Expected entry of drugs with multiple mechanisms and novel technologies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1 Mirapex/Sifrol/Mirapexin
05.2 Requip
05.3 Neupro/Leganto
05.4 HORIZANT/Regnite

06.Introduction

07.Disease Overview
07.1 Understanding RLS
07.1.1 Types of RLS
07.2 Etiology and Pathogenesis
07.2.1 Genetic Factors
07.2.2 Iron Deficiency
07.2.3 Other Disease Conditions/Medications
07.2.4 Neurological Disturbances
07.3 Signs and Symptoms
07.4 Diagnosis
07.4.1 Differential Diagnosis of RLS
07.5 Management
07.5.1 Pharmacological Therapy
07.5.2 Non-pharmacological Therapy
07.6 Epidemiology
07.7 Economic Burden

08.Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 Injectafer
08.1.2 Lisuride
08.1.3 Incobotulinumtoxin A
08.1.4 IPX-159
08.1.5 Safinamide
08.1.6 AZ-008
08.1.7 SER-214

09.Commercial Opportunities

10.Key Brand Analysis

11.Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis

12.Market Segmentation by Class of Drugs
12.1 Dopaminergic Drugs
12.2 Opioids
12.3 Anticonvulsants
12.4 Sedatives and Hypnotics
12.5 Others

13.Geographical Segmentation
13.1 Global Restless Legs Syndrome Market by Geography 2014-2019

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 UCB
21.2.2 GlaxoSmithKline
21.2.3 Boehringer Ingelheim
21.2.4 XenoPort
21.3 Other and Future Prominent Vendors

22.Key Vendor Analysis
22.1 Boehringer Ingelheim
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Geographical Segmentation by Revenue 2013
22.1.6 Business Strategy
22.1.7 Recent Developments
22.1.8 SWOT Analysis
22.2 GlaxoSmithKline
22.2.1 Key facts
22.2.2 Business overview
22.2.3 Business segmentation by revenue 2014
22.2.4 Business segmentation by revenue 2013 and 2014
22.2.5 Geographical segmentation by revenue 2014
22.2.6 Business strategy
22.2.7 Recent developments
22.2.8 SWOT analysis
22.3 UCB
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Product Segmentation by Revenue 2013
22.3.4 Product Segmentation by Revenue 2012 and 2013
22.3.5 Geographical Segmentation by Revenue 2013
22.3.6 Business Strategy
22.3.7 Recent Developments
22.3.8 SWOT Analysis
22.4 XenoPort
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Strategy
22.4.4 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Types of RLS
Exhibit 3: Prevalence of Primary and Secondary RLS 2014
Exhibit 4: Types of RLS based on Onset of Disease
Exhibit 5: Etiology of RLS
Exhibit 6: Symptoms of RLS
Exhibit 7: Differential Diagnosis of RLS
Exhibit 8: Treatment Options for RLS
Exhibit 9: Prevalence of RLS Based on Gender
Exhibit 10: Pipeline Portfolio of Global Restless Legs Syndrome Market
Exhibit 11: Commercial Opportunities for Global Restless Legs Syndrome Market
Exhibit 12: Global Restless Legs Syndrome Market 2014-2019 ($ millions)
Exhibit 13: Global Restless Legs Syndrome Market by Class of Drugs
Exhibit 14: Global Restless Legs Syndrome Market by Geography 2014
Exhibit 15: Vendor Ranking 2014
Exhibit 16: Neupro: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 17: Neupro: Region-wise Revenue Comparison 2012-2014 ($ millions)
Exhibit 18: Requip: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 19: Region-wise Revenue Comparison of Requip 2012-2014 ($ millions)
Exhibit 20: HORIZANT: US Revenue 2013-2014 ($ millions)
Exhibit 21: Regnite: Revenue in Japan 2013-2014 ($ millions)
Exhibit 22: Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 23: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 24: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 25: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 27: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 28: UCB: Product Segmentation by Revenue 2013
Exhibit 29: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 30: UCB: Geographical Segmentation by Revenue 2013



【掲載企業】

Boehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva NeuroscienceBoehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics, Teva Neuroscience

【資料のキーワード】

むずむず脚症候群(RLS、Willis-Ekbom病)、むずむず脚症候群治療薬、製品パイプライン、市場機会、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[むずむず脚症候群(RLS)治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆